Article Text

Download PDFPDF
Prior anti-thrombotic drugs and stroke mortality
  1. M J Alberts
  1. Correspondence to Dr M J Alberts, Department of Neurolgy, Northwestern University Medical School, 710N Lake Shore Drive, Room 1420, Chicago, IL 60611, USA; m-alberts{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The very interesting and provocative paper by Kwok et al1 raises some important questions that have significant implications in terms of the clinical management of patients with haemorrhagic strokes. The Kwok study examined more than 3300 patients in the UK who were hospitalised with either an ischaemic stroke or a haemorrhagic stroke (intracerebral haemorrhage (ICH) only; patients with a subarachnoid haemorrhage were excluded). Almost half of the patients (47%) were taking either an antiplatelet agent or an anticoagulant.

A key finding of this study was that for patients with an ischaemic stroke, the use of either antiplatelet agents or anticoagulants did not impact mortality subsequent to the stroke, looking at intervals ranging from 7 days to 365 days post-ischaemic stroke. The results for patients admitted with a haemorrhagic stroke were quite different, with higher mortality rates for patients taking an antiplatelet agent or anticoagulant among this group. A closer examination of the results shows that much of the difference in outcomes was driven by the higher mortality associated with prior anticoagulant use, with ORs of 2.0 to 2.8 for most models related to anticoagulant use, compared to ORs of 1.5 to 1.8 for antiplatelet use.

Another curious finding is that most of the excess mortality occurred in a bi-modal pattern, with higher morality being seen early (0–30 days) and late (90–365 days) post-stroke. In a related manner, and a significant limitation of this study, is that the actual cause of death was not recorded, due largely to the administrative …

View Full Text


  • Linked articles 301076.

  • Competing interests MJA has been a speaker for Bristol Myers Squibb, Sanofi-Aventis, Boehringer-Ingelheim, and is a consultant for the above entities as well as Janssen and Pfizer.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles